Navigation Links
Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
Date:12/17/2009

- Procedure Provides Efficient Mechanism to Pursue Approval in Multiple Jurisdictions -

LAVAL, QC, Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under the Decentralized Procedure (DCP). The DCP provides an efficient mechanism that allows a company to simultaneously pursue regulatory approval for a medicinal product in multiple jurisdictions in Europe.

"Initiating the regulatory approval process in Europe builds on our recently established marketing partnership with Grunenthal GmbH," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "It is our intention to commercialize our twice-daily tramadol-acetaminophen formulation in key markets around the world. To this end, we are both preparing to submit additional regulatory applications in 2010 and pursuing marketing partners in key regions around the world."

In accordance with the DCP, Labopharm has submitted a marketing authorization application (MAA) with a Reference Member State (Iceland), which will provide an assessment of the MAA file to the Company's list of Concerned Member States. Labopharm is responsible for obtaining regulatory approval in most of the countries included in the distribution and supply agreement with Grunenthal and is seeking approval in those countries. The regulatory authorities of both Reference Member State and Concerned Member States will achieve consensus regarding approval of the product and all Member States grant national Marketing Authorisations based upon that consensus decision. The DCP is expected to take approximately one year to complete and national Marketing Authorizations will be provided thereafter.

The estimated Euro sales i
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Northbound Treatment Services announced today ... Relations. , Emily originally entered the behavioral healthcare industry as an academic ... academic curriculum for clients to engage in their educational journey while in treatment. ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... dedicated to the global distribution and marketing of a number of nutritional and ... when it attended the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... different philosophies and approaches to case management, placement, sober companionship and delivery to ... and approaches to working with and transporting clients with anxiety, ADHD, autism spectrum ...
(Date:7/1/2015)... ... ... The Thule Atmos X4 offers protection with minimal bulk. At the Thule ... rigorous standards. Due to its Bi-ComponentArmor and ShockStop corners, it passed Thule’s 2 meter ... , The Thule Atmos X4 has also been designed with function in mind. ...
(Date:7/1/2015)... (PRWEB) , ... July 01, ... ... in the communities of southeast Alabama, southwest Georgia and the Florida Panhandle, ... TelmedIQ as its primary secure text messaging and clinical communications workflow solution ...
Breaking Medicine News(10 mins):Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2
... 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ... will provide a corporate,overview at the upcoming Collins Stewart ... July 8, 2008 in New York, NY., Interested ... visiting,the Sunesis website at http://ir.sunesis.com . A replay ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... 2 The Michigan Attorney General announced,on July 2 ... Shield of,Michigan challenging a capital transaction between BCBSM and ... position that BCBSM is not,authorized by Public Act 350 ... Accident Fund obtained prior regulatory approval for the,transaction. BCBSM ...
... has spread to distant sites has a poor prognosis, but ... slow disease progression in some patients, a research team led ... Cancer Center reports in the July 3rd edition of ... drug, motesanib diphosphate, is a VEGF inhibitor, a biologic agent ...
... 2 A Miami resident was,sentenced to 130 months ... the,Medicare program, Acting Assistant Attorney General Matthew Friedrich of,the ... the Southern,District of Florida announced today., Gustavo Smith, ... for,the Southern District of Florida by Judge Marcia G. ...
... Hanger Orthopedic,Group, Inc. (NYSE: HGR ) ... Services revised its outlook for Hanger Orthopedic Group, ... corporate credit,rating at "B." "The outlook revision reflects ... improved financial risk profile," said,Standard & Poor,s credit ...
Cached Medicine News:Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2
(Date:7/1/2015)... The Haselmeier Group has decided to reinforce ... has been nominated by the Board of Directors ... (CEO) of the Haselmeier Group. This nomination is ... brings more than 20 years of experience in the ... management positions, the last being Managing Director and Vice ...
(Date:6/30/2015)... -- Inventor of ProTide technology ...   NuCana, a clinical stage biopharmaceutical company ... portfolio of novel anti-cancer medicines, today announced the appointment ... Officer. Professor McGuigan was the original inventor ... Medicinal Chemistry at the Cardiff School of Pharmacy and ...
(Date:6/30/2015)... Ansell, a global leader in protection solutions, ... Ansell Cares ® H.E.R.O. Service Award ... organised in partnership with the European Operating Room Nurses ... and quality in patient care, and present an in-depth ... taking place today in the winners, respective hospitals in ...
Breaking Medicine Technology:Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3Ansell Announces European O.R. Nurse Hero Award Winners 2Ansell Announces European O.R. Nurse Hero Award Winners 3
... SAN DIEGO, May 5, 2011 /PRNewswire/ -- Halozyme ... developing and commercializing products targeting the extracellular matrix , ... of America Merrill Lynch Health Care Conference in Las Vegas. ... PDT (2:10 p.m. EDT). To listen to the live webcast ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... 31, 2011.  Savient ended the quarter with $268.0 million in ... December 31, 2010, primarily due to the issuance and sale ... the first quarter of 2011, the Company had a net ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
Medicine Products: